Hao Sun1, Ting Sun2, Bing Ma3, Bo-wen Yang4, Yao Zhang5, Dong-hui Huang6, Jing-pu Shi7. 1. Department of Clinical Epidemiology and Evidence-based Medicine, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Institute of Cardiovascular Diseases, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Center of Evidence Based Medicine, Liaoning Province & China Medical University, Shenyang 110001, China. Electronic address: ivy_071602@126.com. 2. Department of Clinical Epidemiology and Evidence-based Medicine, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Institute of Cardiovascular Diseases, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Center of Evidence Based Medicine, Liaoning Province & China Medical University, Shenyang 110001, China. Electronic address: 0314ls0930@163.com. 3. Department of Clinical Epidemiology and Evidence-based Medicine, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Institute of Cardiovascular Diseases, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Center of Evidence Based Medicine, Liaoning Province & China Medical University, Shenyang 110001, China. Electronic address: mabing081208@163.com. 4. Department of Clinical Epidemiology and Evidence-based Medicine, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Institute of Cardiovascular Diseases, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Center of Evidence Based Medicine, Liaoning Province & China Medical University, Shenyang 110001, China. Electronic address: damo_yang@sina.com. 5. Department of Clinical Epidemiology and Evidence-based Medicine, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Institute of Cardiovascular Diseases, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Center of Evidence Based Medicine, Liaoning Province & China Medical University, Shenyang 110001, China. Electronic address: zhangyao5102@126.com. 6. Department of Clinical Epidemiology and Evidence-based Medicine, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Institute of Cardiovascular Diseases, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Center of Evidence Based Medicine, Liaoning Province & China Medical University, Shenyang 110001, China. Electronic address: huangcheng8928@163.com. 7. Department of Clinical Epidemiology and Evidence-based Medicine, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Institute of Cardiovascular Diseases, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Center of Evidence Based Medicine, Liaoning Province & China Medical University, Shenyang 110001, China. Electronic address: jingpushi56@yahoo.com.
Abstract
BACKGROUND: Measurement of the biomarker copeptin may help identify disease severity and risk of mortality for a various diseases. This study sought to determine the relationship between copeptin and all-cause mortality of patients with cardio-cerebrovascular disease. METHODS: Database of Medline and Web of Science were searched for studies with data involving the baseline copeptin levels and subsequent all-cause mortality outcomes. The pooled HRs of all-cause mortality were calculated and presented with 95%CIs. Subgroup analysis and sensitivity analysis were conducted to explore the possible sources of heterogeneity. RESULTS: Data from 14,395 participants were derived from 28 prospective studies. Higher copeptin significantly increased the risk of all-cause mortality (per unit copeptin: HR=1.020, 95%CI=1.004-1.036; log unit copeptin: HR=2.884, 95%CI=1.844-4.512; categorical copeptin: HR=3.371, 95%CI=2.077-5.472). Subgroup analysis indicated that the risk of all-cause death was higher in cerebrovascular patients (per unit copeptin: HR=2.537, 95%CI=0.956-6.731; log unit copeptin: HR=3.419, 95%CI=2.391-4.888) than cardiovascular patients (per unit copeptin: HR=1.011, 95%CI=1.002-1.020; log unit copeptin: HR=2.009, 95%CI=1.119-3.608). CONCLUSION: Copeptin is associated with all-cause mortality of patients with cardiovascular and cerebrovascular disease. Our study suggests that copeptin seems to be a promising novel biomarker for prediction of mortality in cardio-cerebrovascular patients, especially for cerebrovascular patients.
BACKGROUND: Measurement of the biomarker copeptin may help identify disease severity and risk of mortality for a various diseases. This study sought to determine the relationship between copeptin and all-cause mortality of patients with cardio-cerebrovascular disease. METHODS: Database of Medline and Web of Science were searched for studies with data involving the baseline copeptin levels and subsequent all-cause mortality outcomes. The pooled HRs of all-cause mortality were calculated and presented with 95%CIs. Subgroup analysis and sensitivity analysis were conducted to explore the possible sources of heterogeneity. RESULTS: Data from 14,395 participants were derived from 28 prospective studies. Higher copeptin significantly increased the risk of all-cause mortality (per unit copeptin: HR=1.020, 95%CI=1.004-1.036; log unit copeptin: HR=2.884, 95%CI=1.844-4.512; categorical copeptin: HR=3.371, 95%CI=2.077-5.472). Subgroup analysis indicated that the risk of all-cause death was higher in cerebrovascularpatients (per unit copeptin: HR=2.537, 95%CI=0.956-6.731; log unit copeptin: HR=3.419, 95%CI=2.391-4.888) than cardiovascularpatients (per unit copeptin: HR=1.011, 95%CI=1.002-1.020; log unit copeptin: HR=2.009, 95%CI=1.119-3.608). CONCLUSION:Copeptin is associated with all-cause mortality of patients with cardiovascular and cerebrovascular disease. Our study suggests that copeptin seems to be a promising novel biomarker for prediction of mortality in cardio-cerebrovascularpatients, especially for cerebrovascularpatients.
Authors: Philipp Baumann; Verena Gotta; Andrew Atkinson; Markus Deisenberg; Martin Hersberger; Adam Roggia; Kevin Schmid; Vincenzo Cannizzaro Journal: Children (Basel) Date: 2022-05-28
Authors: Michael John Stacey; Simon K Delves; Sophie E Britland; Adrian J Allsopp; Stephen J Brett; Joanne L Fallowfield; David R Woods Journal: Eur J Appl Physiol Date: 2017-10-27 Impact factor: 3.078